Kurser indlæses...

Prognose

Analytikernes gennemsnitlige kursmål er 58,09 € (+2.271,02 %). Medianen er 37,08 € (+1.413,47 %).

Køb	4
Behold	14
Sælg	2

Nyheder Til nyhedsfeedet

Tilray Brands (ex Aphria) raises quarterly revenue to USD 257.2 million (+22.7%)

Tilray Brands (ex Aphria) reported for the quarter ended August 31, 2026 a revenue increase of 22.74% to USD 257.2 million, compared with USD 209.5 million a year earlier. The earnings figure was released on October 8, 2026. » Mere på finanzen.net
Tilray invests £50m in BrewDog to improve beers, pubs and working conditions

Tilray, which bought BrewDog in March for £33m after the brewer entered administration, is investing more than £50m to improve beer quality, reopen and upgrade selected bars, raise pay and improve working conditions. The company is upgrading the Aberdeenshire brewery, launching new beers, introducing US craft lines into BrewDog venues and considering further UK craft acquisitions. Administrators said creditors will not be repaid in full and crowdfunding shares were rendered worthless, though some investor benefits and supplier continuity have been maintained. » Mere på theguardian.com
Tilray positioned to benefit if Trump advances marijuana rescheduling

A federal appeals court refused to pause the Biden administration's move to consider broader rescheduling of marijuana, keeping alive a proposal to reclassify cannabis to Schedule III. Schedule III would not legalize recreational use or interstate commerce but could ease research and expand medical opportunities that would help Tilray's international medical cannabis business. Tilray reported record fiscal 2026 revenue, sharply improved cash flow and near-elimination of net debt, and management sees U.S. rescheduling as a future growth opportunity. Legal challenges and timing remain uncertain, so potential investors should view rescheduling as upside rather than a guaranteed catalyst. » Mere på finance.yahoo.com

Historisk udbytte Udbytte

Alle nøgletal for udbytte Alle nøgletal

I 2022 har Tilray allerede udloddet 0,10 € i udbytte. Den seneste udlodning fandt sted i juni 2022.

Virksomhedstal

I det seneste kvartal havde Tilray en omsætning på 221,35 mio. € og et nettoresultat på -37,13 mio. €

(EUR)	august 2026	YoY
Omsætning	221,35 mio.	23,51 %
Bruttofortjeneste	66,72 mio.	35,72 %
Nettoresultat	-37,13 mio.	13.382,06 %
EBITDA	-11,35 mio.	161,77 %

Fundamentale data

Nøgletal	Værdi
Markedsværdi	264,29 mio. €
Antal aktier	111,83 mio.
Højeste/laveste i 52 uger	14,03 € - 2,35 €
Udbytte	Nej
Beta	1,92
P/E (PE Ratio)	-1,89
PEG (PEG Ratio)	-0,02
K/I (PB Ratio)	0,22
P/S (PS Ratio)	0,31

Virksomhedsprofil

Tilray Brands Inc. beskæftiger sig med forskning, dyrkning, produktion, markedsføring og distribution af medicinske cannabisprodukter. Virksomheden er organiseret i fem segmenter: Cannabisforretning, Distributionsforretning, Forretning med alkoholiske drikkevarer, Wellnessforretning og Forretning under udvikling. Selskabet leverer medicinske og voksenrettede cannabisprodukter, farmaceutiske produkter og wellnessprodukter, alkoholiske drikkevarer samt hampbaserede fødevarer og andre wellnessprodukter. Produkterne sælges til detailhandlere, grossister, patienter, læger, apoteker, klinikker, hospitaler, offentlige myndigheder og forskere. Virksomheden driver Tilray Medical, en medicinsk platform, der tilbyder GMP-certificerede blomster, olier, vapes, spiselige produkter og topikale produkter. Selskabet har aktiviteter i Canada, USA, Europa, Australien, New Zealand, Latinamerika og internationalt. Virksomheden var tidligere kendt som Tilray, Inc. Tilray Brands Inc. blev stiftet i 2018 og har hovedkontor i New York, New York.